Country Focus
Others
First posted: 25 May 2012
The Italian pharmaceutical market is poorly developed* in the use of generic medicines.
Others
First posted: 24 August 2012
The French generics market is poorly developed* and is one of the smaller markets in Europe by both volume and value.
Others
First posted: 14 October 2013
Concerning biosimilars approved and marketed in Germany, view the following related articles:
Biosimilars approved and marketed in Germany
Germany wants to increase biosimilars penetration
Germany is already a mature (well-established) market* in the use of generic medicines.
Others
First posted: 14 November 2013
Poland is already a mature (well-established) market* in the use of generic medicines.
Others
First posted: 12 August 2011
Concerning biosimilars approved and marketed in The Netherlands, view the following related article:
Biosimilars approved and marketed in The Netherlands
The Netherlands is already a mature (well-established) market* in the use of generic medicines.
Others
First posted: 12 August 2011
Concerning biosimilars approved and marketed in Belgium, view the following related article:
Biosimilars approved and marketed in Belgium
The Belgian generics market is poorly developed* and is among the smallest in Europe by both volume and value.
Policies and Legislation
First posted: 12 August 2011
Concerning biosimilars policies in the UK, view the following related articles:
UK outlines process for developing biosimilars guidances
In the UK generic pricing is regulated by the voluntary Pharmaceutical Price Regulation Scheme (PPRS), enabling free pricing.
Policies and Legislation
First posted: 17 October 2011
Concerning biosimilars policies in Spain, view the following related article:
Spain does not have a coherent generic medicines policy and there is no generic medicines competition within the existing regulatory frameworks [1].
Policies and Legislation
First posted: 6 December 2011
View the article below to learn of measures to change prescribing patterns of angiotensin receptor blockers:
Policies and Legislation
First posted: 15 March 2012
Portugal does not have a coherent generic medicines policy and there is no generic medicines competition within the existing regulatory frameworks [1].
